Interest of the disk diffusion method for screening Clostridium difficile isolates with decreased susceptibility to antibiotics;Évaluation de l'antibiogramme par diffusion en milieu gélosé pour le dépistage de souches de Clostridium difficile de sensibilité diminuée aux antibiotiques

Pathologie Biologie

Volumn 55, Issue 8-9, 2007, Pages 429-433

  Poilane, I ^a   Bert, F ^b   Cruaud, P ^a   Nicolas Chanoine, M H ^b   Collignon, A ^a  

^a HÔPITAL JEAN VERDIER   (France)

^b BEAUJON HOSPITAL   (France)

Author keywords

Antibiotic susceptibility testing; Clostridium difficile; Disk diffusion method

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFTRIAXONE; CHLORAMPHENICOL; ERTAPENEM; ERYTHROMYCIN; GLYCOPEPTIDE; IMIPENEM; LEVOFLOXACIN; LINCOMYCIN; LINEZOLID; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

AGAR GEL DIFFUSION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CLOSTRIDIUM DIFFICILE; IN VITRO STUDY; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SHEEP; CLASSIFICATION; DIFFUSION; DOSE RESPONSE; DRUG EFFECT; FRANCE; HOSPITAL; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DIFFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FRANCE; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 35448975668     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2007.07.010     Document Type: Article

References (18)

1. Pituch H., Obuch-Woszczatynski P., Wultanska D., Meisel-Mikolajczyk F., and Luczak M. A survey of metronidazole and vancomycin resistance in strains of Clostridium difficile isolated in Warsaw, Poland. Anaerobe 11 (2005) 197-199
2. Barbut F., Delmée M., Brazier J.S., Petit J.C., Poxton I.R., Rupnik M., et al. A European survey of diagnostic methods and testing protocols for Clostridium difficile. Clin. Microbiol. Infect. 9 (2003) 989-996
3. Gerding D.N. Metronidazole for Clostridium difficile-associated disease: is it okay for Mom?. Clin. Infect. Dis. 40 (2005) 1598-1600
4. Musher D.M., Aslam S., Logan N., Nallacheru S., Bhaila I., Borchert F., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40 (2005) 1586-1590
5. Wong S.S., Woo P.C., Luk W.K., and Yuen K.Y. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn. Microbiol. Infect. Dis. 34 (1999) 1-6
6. Barry A.L., Fuchs P.C., Gerlach E.H., Allen S.D., Acar J.F., Aldridge K.E., et al. Multilaboratory evaluation of an agar diffusion disk susceptibility test for rapidly growing anaerobic bacteria. Rev. Infect. Dis. 12 (1990) S210-S217
7. Barbut F., Decré D., Burghoffer B., Lesage D., Delisle F., Lalande V., et al. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob. Agents Chemother. 43 (1999) 2607-2611
8. Ackermann G., Degner A., Cohen S.H., Silva Jr. J., and Rodloff A.C. Prevalence and association of macrolide-lincosamide-streptogramin B (MLSB) resistance with resistance to moxifloxacin in Clostridium difficile. J. Antimicrob. Chemother. 51 (2003) 599-603
9. Drummond L.D., McCoubrey J., Smith D.G.E., Starr J.M., and Poxton I.R. Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period. J. Med. Microbiol. 52 (2003) 259-263
10. Pelaez T., Alcal L., Alonso R., Rodriguez-Creixems M., Garcia-Lechuz J.M., and Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob. Agents Chemother. 46 (2002) 1647-1650
11. Pelaez T., Alonso R., Pérez C., Alcala L., Cuevas O., and Bouza E. In vitro activity of linezolid against Clostridium difficile. Antimicrob. Agents Chemother. 46 (2002) 1617-1618
12. Ackermann G., Adler D., and Rodloff A.C. In vitro activity of linezolid against Clostridium difficile. J. Antimicrob. Chemother. 51 (2003) 743-745
13. Goldstein E.J.C., Citron D.M., Vreni Merriam C., Warren Y.A., Tyrrel K.L., and Fernandez H. Comparative in vitro activities of Ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections. Antimicrob. Agents Chemother. 46 (2002) 1136-1140
14. Wexler H.M., Engel A.E., Glass D., and Li C. In vitro activities of Doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob. Agents Chemother. 49 (2005) 4413-4417
15. Alonso R., Pelaez T., Gonzalez-Abad M.J., Alcala L., Munoz P., Rodriguez-Creixems M., et al. In vitro activity of new quinolones against Clostridium difficile. J. Antimicrob. Chemother. 47 (2001) 195-197
16. Wilcox M.H., Fawley W., Freeman J., and Brayson J. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. J. Antimicrob. Chemother. 46 (2000) 551-555
17. Gerding D.N. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin. Infect. Dis. 38 (2004) 646-648
18. Von Baum H., Sigge A., Bommer M., Kern W.V., Marre R., Dohner H., et al. Moxifloxacin prophylaxis in neutropenic patients. J. Antimicrob. Chemother. 58 (2006) 891-894